Metformin treatment reduced plasma C-reactive protein levels and monocyte release of tumor necrosis factor - and interleukin-6 , as well as tended to reduce monocyte release of interleukin-1 and monocyte chemoattractant protein-1 , which was accompanied by an improvement in insulin sensitivity .